- Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test - SALT LAKE CITY, April 28, 2021-- Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the completion of a $100 million Series E financing. Several leading healthcare-focused institutional investors have joined this financing round, including Vivo Capital, aMoon Fund, Parian Global, and others, led by existing investors Anthem, Inc., and Blue Ox Healthcare Partners.